Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Industry Urges Caution In Response To Growing Push For 'Real-World' Device Evaluation System

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed's new chief Scott Whitaker says industry doesn't want to sign onto a new "national evaluation system" for devices championed by FDA until it is convinced that the initiative will enhance, rather than hinder, premarket product development.


Related Content

Real-World Evidence User-Fee Funding Praised At FDA Meeting
Pilot Of New US Evaluation System Will Include At Least Two Devices
In Case You Missed It: Top 10 Gray Sheet Stories In June
Real-World Evidence Is Versatile, Commissioner Califf Says: 'Use It For The Right Purposes'
Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed
Califf Puts Weight Behind 'Sentinel' As Evidence-Generation System Of The Future
Senate Moves To Floor Phase For Innovation Bill; Postmarket Surveillance, LDTs Could Get Attention
CDRH Prioritizes Leveraging Real-World And Patient-Preference Data, Enhancing Quality
Scope Firms, FDA Faulted In 300-Page Senate Report Seeking Device Reforms
Shuren Touts Pre-Market Benefits Of Planned National Post-Market Strategy